Break The Cell Therapy Manufacturing Bottleneck With Day-0 Transduction, Day-3 Harvest

Cell therapies, such as CAR-T, are poised for a significant leap forward, driven by the critical need for faster, more reliable, and scalable manufacturing. While existing T-cell therapies have shown great clinical success, their traditional activation and expansion methods are bottlenecked. These conventional processes can take 9–14 days, involve numerous manual, open-handling steps, and often yield inconsistent results when using material derived from different patients. Such limitations lead to manufacturing failures, escalating costs, and unacceptable delays in patient care.

Discover groundbreaking data on Synecta™ T1 cell-derived nanoparticles (CDNPs). These nanoparticles are engineered to drastically accelerate T-cell activation. Comparative studies demonstrate that CDNPs enable earlier transduction (Day-0), support robust expansion, and maintain high cell viability across both healthy donor and challenging patient samples—and they do it without the need for additional cytokine supplementation.

The flexibility of the CDNP platform was shown in both rapid and conventional manufacturing workflows, preserving the desired T-cell phenotypes while significantly simplifying the process and minimizing complex manipulation steps.

This webinar also explores the unique mechanism of CDNPs, which mimics natural physiological immune stimulation. This positioning makes them an ideal advanced activation platform for a wide range of T-cell therapy modalities.